Hims and Hers acquires Livewell ahead of generic Ozempic launch in Canada [Yahoo! Finance Canada]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: Yahoo! Finance Canada
recent acquisition of Livewell, an online telehealth platform focused on weight loss The United States telehealth upstart said the move is expected to help accelerate its platform's official launch in Canada next year. Hims & Hers' planned launch is timed to align with the first anticipated availability of generic semaglutide anywhere in the world. The drug, popularized by the brand Ozempic and used in the treatment of type 2 diabetes, has been widely prescribed as an anti-obesity medication. “Our expansion into Canada is a direct response to critical public health needs, particularly around the obesity crisis,” Andrew Dudum, co-founder and chief executive of Hims & Hers, said in a press release. The company said it is establishing a local team to lead the Canadian operations. Austin Kouri, a former DoorDash executive, will lead as the general manager of Hims & Hers Canada, working closely with advisor and new chief medical officer in Canada, obesity physician Dr. Sandy Van.
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Novo Nordisk A/S (NYSE:NVO) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.MarketBeat
- Update: Novo Nordisk Loses India Case to Halt Dr. Reddy's Production of Generic Semaglutide [Yahoo! Finance]Yahoo! Finance
- Novo Nordisk still sees potential for GLP-1 drugs for Alzheimer's, despite trial setback [MSNBC.com]MSNBC.com
- Novo Nordisk A/S (NVO): A Bull Case Theory [Yahoo! Finance]Yahoo! Finance
- 4 stocks to watch on Thursday: NVO, PLTR, DG, PSKY [Seeking Alpha]Seeking Alpha
NVO
Earnings
- 11/6/25 - Beat
NVO
Sec Filings
- 11/25/25 - Form 6-K
- 11/24/25 - Form 6-K
- 11/17/25 - Form 6-K
- NVO's page on the SEC website